linjc16/ctgov huggingface dataset:
Effects of Budesonide & Budesonide/Formoterol on Smoking Asthmatic Subjects

Study Overview
=================
Brief Summary
-----------------
A reduced response to inhaled corticosteroids (ICS) has been reported in smoking compared to non-smoking asthmatic patients. However, the comparative response to other currently prescribed medications such as combination therapy of long-acting beta agonists and ICS remain to be further evaluated. No significant differences were found between our group of subjects in regard to changes in asthma control pulmonary function and airway inflammation following budesonide or the association of budesonide with formoterol for a period of 2 months. This should be further explored in larger groups of subjects.

Official Title
-----------------
Comparative Effects of Budesonide and Budesonide/Formoterol (Symbicort) on Asthma Control in Smoking Asthmatic Subjects: A Pilot Study

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: budesonide and budesonide/formoterol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Asthmatic non-smokers or ex-smokers (less than 10 pack/years) Asthmatic smokers (more than 5 cigarettes a day and more than 5 pack/years FEV1 greater than 70% No more than 3 doses of rescue medication (bronchodilator) per day Exclusion Criteria: Mentally or legally incapacitated thus preventing informed consent from being obtained Other pulmonary disorder History of upper respiratory tract infection in the last month Pregnant or lactating women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: budesonide and budesonide/formoterol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparative changes before and after treatments in each group for Asthma Control Questionnaire (ACQ) |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Other control scores (ACSS score) and rescue B2 agonist need |  |  | 
| Comparative changes in FEV1 |  |  | 
| Quality of life questionnaire |  |  | 
| Morning and evening PEF |  |  | 
| Total and differential cell counts in induced sputum and ECP and MPO |  |  |
Stablishment of Prevention and Treatment System for Intestinal Dysfunction

Study Overview
=================
Brief Summary
-----------------
Dysfunction and intestinal endocrine dysfunction. This project will use genomics, metabonomics, microbiome and other omics techniques to study the clinical pathway of CID integrated therapy.

Official Title
-----------------
The Goal-direct Treatment of Chronic Bowel Dysfunction

Conditions
-----------------
Bowel Dysfunction

Intervention / Treatment
-----------------
* Drug: Nutritional Therapy, Metabolic Disorder, Regular


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The Patients with chronic bowel dysfunction Exclusion Criteria: Past severe underlying diseases of the respiratory system and cardiovascular system, Allergy to treatment-related drugs, Pregnancy, Accept CID surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: Intestinal dysfunction is defined as the damage of intestinal substance and/or function, which leads to digestion, absorption and/or mucosal barrier function.
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: living quality<br> | Drug: Nutritional Therapy, Metabolic Disorder, Regular<br>* According to the result reported by Byrne, Wilmore, etc. in 1992   1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.<br>|
| Experimental: complication<br> | Drug: Nutritional Therapy, Metabolic Disorder, Regular<br>* According to the result reported by Byrne, Wilmore, etc. in 1992   1995, the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment. Then, check the patient's quality of life survey, nutritional status, inflammation indicators and other changes every three months, and use metabolomics and microbiomic tools to detect changes in the patient's nutritional metabolism, intestinal microecology, etc., and adjust the patient's nutritional treatment and microecological treatment based on the results Program.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| nutrition index |  | 3 years |
Paravertebral Block vs. Suprascapular Block for Treatment of Frozen Shoulder

Study Overview
=================
Brief Summary
-----------------
Background: Adhesive capsulitis, or frozen shoulder, is a major orthopedic condition that causes pain and functional limitation. Although different nonsurgical conservative therapies such as physical therapy, nonsteroidal anti-inflammatory drugs, and corticosteroid injections have been used, yet there is no standard treatment for frozen shoulder. Objectives: The primary objective of this study is to compare the effectiveness of nerve stimulator guided paravertebral block versus suprascapular block for treatment of frozen shoulder. The primary outcome is pain measured through the Visual Analogue Scale (VAS) over a follow up period of 6 months. Methods: This is a prospective randomized clinical trial that will be conducted between February 2021 and January 2022. Patients will be randomly allocated into two groups. Group I will receive paravertebral block guided by a nerve stimulator. Group II patients will receive suprascapular nerve block. Patients will be followed up at week 1, month 1, month 3 and month 6.

Official Title
-----------------
Paravertebral Block Versus Suprascapular Block for Treatment of Frozen Shoulder: a Prospective, Randomized Clinical Trial

Conditions
-----------------
Pain, Shoulder

Intervention / Treatment
-----------------
* Other: Paravertebral block
* Other: Suprascapular block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and older presenting with frozen shoulder and were unresponsive to conservative therapy Exclusion Criteria: Complete rotator cuff tear Osteoarthritis Calcified tendinitis History of shoulder joint injury Cervical radiculopathy Bleeding disorder Active infection Allergy to Bupivacaine Diabetes Mellitus

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Paravertebral block<br>Patients will receive paravertebral block guided by a nerve stimulator. | Other: Paravertebral block<br>* Paravertebral block using nerve stimulator guidance will be done at C7-T1<br>|
| Active Comparator: Suprascapular block<br>Patients will receive suprascapular block | Other: Suprascapular block<br>* Paravertebral block using nerve stimulator guidance will be done<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain score | Pain will measured through the Visual Analogue Scale (VAS). 0 indicates no pain and 10 indicates maximum pain | 6 months |
Photodynamic Therapy of Actinic Keratoses With Alacare®

Study Overview
=================
Brief Summary
-----------------
This study aims to collect data on the frequency of SCCs in the Alacare®-treated area during an interval of two years after Alacare®-PDT.

Official Title
-----------------
Non-interventional Observational Study on Photodynamic Therapy of Actinic Keratoses With Alacare®

Conditions
-----------------
Actinic Keratosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent Patients with 3 to 6 mild AK lesions on the hairless areas of the head and face which were treated with Alacare®-PDT according to the SPC

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of SCCs in areas treated with Alacare®-PDT |  | Two years after Alacare®-PDT |
Vitrification Versus Spontaneous Conception and Slow- Rate Freezing

Study Overview
=================
Brief Summary
-----------------
Great scientific effort has been made to improve practical as well as economical procedures of modern assisted reproduction. In the last years a shift from the well established method of slow-rate freezing to vitrification of 2PN zygotes and embryos could be observed. Like any other method of cryopreservation, the outcome of vitrification will be affected by several factors related to technique itself, its practical management and patient characteristics. The investigators want to investigate the influence of vitrification on the outcome of of 2PN oocytes, pregnancy and infant health. A Comparison between a cohort of spontaneous conceived children and children of vitrified and slow- cooled 2PN oocytes is planned.

Official Title
-----------------
Maternal Pregnancy and Neonatal Outcome After Assisted Reproduction. Comparison of Vitrification vs. Spontaneous Conception

Conditions
-----------------
Pregnancy

Intervention / Treatment
-----------------
* Other: Observation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: cryopreservation (vitrification and slow- rate freezing) between 1998 - 2010 Treatment in Lübeck University Delivery in Lübeck University Positive informed consent Exclusion Criteria: Negative informed consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Spontaneous<br>Mothers with children conceived after spontaneous cycle | Other: Observation<br>* Alberta infant motor scale Griffiths test Kauffmann ABC<br>|
| Vitrificatíon<br>Mothers with children conceived after vitrification cycle | Other: Observation<br>* Alberta infant motor scale Griffiths test Kauffmann ABC<br>|
| slow- rate freezing<br>Mothers with children conceived after slow- rate freezing cycle | Other: Observation<br>* Alberta infant motor scale Griffiths test Kauffmann ABC<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maternal pregancy outcome | spontaneous or operative delivery, birth injuries, conjoined morbidity | 7 years | 
| embryo survival | embryo survival rate | 7 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| infant health | infant vital characteristics (APGAR, arterial cord ph), infant development: only develomental milestones: sitting, standing, walking infant morbidity | 7 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitrification, 2PN oocyte, maternal and infant health, embryo survival, clinical pregnancy rate, mode of delivery, injury during delivery, infant development, infant morbidity, slow- rate freezing
Physicians' Health Study

Study Overview
=================
Brief Summary
-----------------
To assess the effect on cardiovascular mortality of alternate-day consumption of 325 milligrams of aspirin and, secondarily, the effect on cancer incidence of alternate-day consumption of 50 milligrams of beta-carotene.

Detailed Description
-----------------
BACKGROUND: Thrombosis plays a major role in the late stages of coronary occlusion. Platelet aggregation is a large component in the formation of arterial thrombi. In pharmacologic studies, aspirin has been shown to inhibit platelet aggregation and, therefore, might be expected to prevent coronary occlusion. These effects are apparent in the dose range of l00-l000 mg/day, and may be most evident at l60 milligrams daily. Higher doses seem to be no more effective in either inhibition of platelet agreeability or prolonged bleeding time. Although an early case-control study by Jick and Miettinen showed a large benefit, most observational studies had shown a cardiovascular benefit of about 20 percent. Conclusive data could only result from a randomized trial with a large sample size. DESIGN NARRATIVE: Randomized, double-blind, fixed sample. Participants were randomized into one of four treatment groups: one 325 milligram aspirin tablet every other day, alternating with one 30 milligram capsule of beta-carotene; one aspirin every other day, alternating with one capsule of beta-carotene placebo; one aspirin placebo tablet every other day, alternating with one capsule of beta-carotene; and one aspirin placebo tablet every other day, alternating with one capsule of beta-carotene placebo. Major endpoints for the cardiovascular component of the study were cardiovascular mortality, total mortality, and coronary events.

Conditions
-----------------
Heart Diseases, Cardiovascular Diseases, Coronary Disease, Myocardial Ischemia

Intervention / Treatment
-----------------
* Drug: aspirin
* Drug: carotene


Participation Criteria
=================
Eligibility Criteria
-----------------
Male physicians, ages 40 to 84. No history of stroke, myocardial infarction, cancer, or renal disease. No contraindications to aspirin or beta-carotene. No current usage of aspirin or Vitamin A tables greater than once per week.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 84 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: aspirin|nan|
|Drug: carotene|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Pilot for a Community Pharmacy Service Model: Impact of a Pharmacist Monitored Patient Blood Pressure Readings

Study Overview
=================
Brief Summary
-----------------
This study is designed to explore whether routine measurement of blood pressure by community pharmacists can improve patient adherence to blood pressure medications. The study will utilize an incentivized care approach, in which patients receive a $10 gift card for every time they come to the pharmacy for blood pressure management (up to 2 times/month). The investigators hypothesize that the simple process of coming in for a blood pressure measurement (without any other scripted interventions, counseling, or consultation) will be feasible and sufficient to improve adherence to medications. The investigators will also collect preliminary data to help estimate how these hypothetical improvements in adherence might result in improved blood pressure control, fewer office visits, and (ultimately) fewer adverse cardiovascular outcomes (i.e. heart attacks, strokes, etc).

Official Title
-----------------
Pilot for a Community Pharmacy Service Model: Impact of a Pharmacist Monitored Patient Blood Pressure Readings

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Other: Incentivized Care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years Diagnosis of hypertension Current prescription for ≥2 antihypertensive medications for primary diagnosis of hypertension Prior use of ≥1 antihypertensive medication for ≥6 months at the same Kroger's Pharmacy (#523) Willing and able to provide written informed consent Exclusion Criteria: Age <18 years New diagnosis of hypertension within the prior 6 months Current pregnancy or lactation Limited English Proficiency Use of antihypertensive medications for secondary prevention of cardiovascular events. Patients with history of acute myocardial infarction, stroke, heart failure will be excluded, however, patients with diabetes will be eligible for participation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Incentivized Care<br>Patients will meet with the pharmacist up to 2 times/month for blood pressure measurement. Patients will receive a $10 gift card for each measurement. | Other: Incentivized Care<br>* Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Feasibility | Percentage of blood pressure measurements completed | 6 months |
Metabolic Syndrome and Contrast Induced Nephropathy

Study Overview
=================
Brief Summary
-----------------
Prevention of contrast induced nephropathy after interventional cardiologic procedures deserves close interest because of its association with prolonged hospitalization, increased cost and increased in hospital and long term mortality rates. An observational prospective cohort study was designed to determine whether metabolic syndrome predicts the development of contrast induced nephropathy after elective percutaneous coronary intervention.

Official Title
-----------------
Impact of Metabolic Syndrome on Development of Contrast Induced Nephropathy After Elective Percutaneous Coronary Intervention

Conditions
-----------------
Contrast Induced Nephropathy, Metabolic Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be scheduled for elective percutaneous coronary intervention Clinical diagnosis of metabolic syndrome Patients must give informed consent Exclusion Criteria: Acute coronary events Acute renal failure End stage renal failure requiring hemodialysis Contrast allergy and exposure to nephrotoxic agent within 1 week before percutaneous coronary intervention Exposure to contrast agent within 1 week before the procedure.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| metabolic syndrome<br>Presence of 3 or more of these components: high fasting glucose (fasting serum glucose ≥ 100 mg/dl or drug treatment for elevated blood glucose), abdominal obesity (given as waist circumference > 102 cm in men and > 88 cm in women), high blood pressure (≥130/≥85 mmHg or drug treatment for hypertension), hypertriglyceridemia (serum triglycerides ≥150 mg/dl), low high-density lipoprotein cholesterol (<40 mg/dl in men and <50 mg/dl in women). | |
| control<br>Age and sex adjusted control subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Contrast induced nephropathy | Contrast induced nephropathy was defined as an increase in serum creatinine of >25% or >0.5 mg/dl above the baseline value 24 or 48 hours after angiography. | 24-48 hours after the percutaneous coronary intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| glomerular filtration rate | Glomerular filtration rate was estimated using the Cockcroft-Gault formula: (140-age) x weight (kg)/ serum creatinine (mg/dl) x 72 (x 0.85 for females) | 48 hours after the percutaneous coronary intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
creatinine, glomerular filtration rate, metabolic syndrome